We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-5.05%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.37B
AUM Growth
-$155M
Cap. Flow
-$860M
Cap. Flow %
-25.49%
Top 10 Hldgs %
37.46%
Holding
92
New
13
Increased
23
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$85.8M
2
KROS icon
Keros Therapeutics
KROS
+$61.7M
3
LEGN icon
Legend Biotech
LEGN
+$59.5M
4
TMO icon
Thermo Fisher Scientific
TMO
+$49.3M
5
GERN icon
Geron
GERN
+$28M

Top Sells

Rank Stock Value
1
PEN icon
Penumbra
PEN
+$40.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$39M
3
ARVN icon
Arvinas
ARVN
+$31.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$30.9M
5
DXCM icon
DexCom
DXCM
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 66.36%
2 Miscellaneous 33.64%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
26
Intuitive Surgical
ISRG
$132B
$39.3M 1.17%
75,300
-16,000
-18% -$8.33M
ATEC icon
27
Alphatec Holdings
ATEC
$1.46B
$39.1M 1.16%
4,256,490
+215,425
+5% +$1.72M
BNTX icon
28
BioNTech
BNTX
$25.6B
$35.3M 1.05%
309,865
+62,115
+25% +$7.09M
BCAX
29
Bicara Therapeutics
BCAX
$1.55B
$34.9M 1.03%
2,000,659
+343,059
+21% +$7.14M
KRYS icon
30
Krystal Biotech
KRYS
$10.4B
$31.4M 0.93%
200,500
+31,809
+19% +$5.64M
HROW icon
31
Harrow
HROW
$1.4B
$30.4M 0.9%
907,039
+467,401
+106% +$20.7M
KROS icon
32
Keros Therapeutics
KROS
$219M
$30M 0.89%
1,894,439
+1,187,199
+168% +$61.7M
ORKA
33
Oruka Therapeutics
ORKA
$6.03B
$27.1M 0.8%
1,147,676
+631,950
+123% +$15.4M
DNTH icon
34
Dianthus Therapeutics
DNTH
$5.92B
$26.3M 0.78%
1,206,589
+712,902
+144% +$18.3M
KIDS icon
35
OrthoPediatrics
KIDS
$617M
$25.7M 0.76%
1,107,770
– –
IMTX icon
36
Immatics
IMTX
$1.44B
$24.9M 0.74%
3,503,965
+1,856,400
+113% +$16M
GERN icon
37
Geron
GERN
$970M
$24.8M 0.74%
+7,006,315
New +$28M
IRWD icon
38
Ironwood Pharmaceuticals
IRWD
$682M
$24.1M 0.71%
5,440,277
+1,002,045
+23% +$4.07M
BRKR icon
39
Bruker
BRKR
$8.7B
$20.7M 0.61%
+353,200
New +$20.9M
EXAS
40
DELISTED
Exact Sciences
EXAS
$19.8M 0.59%
353,000
+66,822
+23% +$4.16M
NUVL
41
DELISTED
Nuvalent
NUVL
$18.9M 0.56%
+241,235
New +$22.5M
PCVX icon
42
Vaxcyte
PCVX
$8.9B
$18.2M 0.54%
222,424
-75,144
-25% -$7.46M
REPL icon
43
Replimune Group
REPL
$1.46B
$17.9M 0.53%
1,477,102
-1,593,735
-52% -$19.4M
DYN icon
44
Dyne Therapeutics
DYN
$4.68B
$16M 0.48%
+681,182
New +$20.1M
JSPR icon
45
Jasper Therapeutics
JSPR
$23.3M
$15.3M 0.45%
714,658
+231,358
+48% +$4.82M
CGEM icon
46
Cullinan Oncology
CGEM
$1.4B
$14.3M 0.42%
1,176,173
– –
XNCR icon
47
Xencor
XNCR
$1.94B
$14.1M 0.42%
615,531
+149,083
+32% +$3.43M
CADL icon
48
Candel Therapeutics
CADL
$1B
$13.9M 0.41%
+1,600,000
New +$9.45M
RCUS icon
49
Arcus Biosciences
RCUS
$3.72B
$11.9M 0.35%
+802,100
New +$13.1M
CELC icon
50
Celcuity
CELC
$4.33B
$11.6M 0.34%
884,306
– –
1
2
3 4

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q4 2024 Portfolio in Review

As of Q4 2024, Braidwell held 92 positions worth $3.37B, down 4.4% from $3.53B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $860M in Q4 2024, closing 19 positions and reducing 14 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Transmedics worth $57.5M.

  • Braidwell's largest Q4 2024 buy was Transmedics: 922,100 shares worth $57.5M.
  • Braidwell added most to Keros Therapeutics in Q4 2024, an estimated $61.7M increase.
  • Braidwell's biggest Q4 2024 reduction was Penumbra, cutting an estimated $40.4M.
  • Braidwell fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $39M.
  • Braidwell's ten largest holdings make up 37% of its $3.37B portfolio in Q4 2024.
  • Braidwell opened 13 new positions and closed 19 in Q4 2024.
  • Braidwell's portfolio value fell 4.4% quarter-over-quarter to $3.37B.

Based on Braidwell's 13F filing for Q4 2024, filed 14 Feb 2025.